MedTrace Logo

An Opioid Prescribing Nudge

NCT04069403 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 427

Last updated 2020-06-30

No results posted yet for this study

Summary

Analyze baseline concurrent opioid prescribing metrics at the individual prescriber level in the Duke Health System on the identified three main outcome measures.

Test the impact of reports on opioid prescriber behaviors with the following primary measures: number of prescriptions with concurrent benzo within reporting period, number of prescriptions with concurrent muscle relaxants within reporting period, and number of encounters with naloxone prescriptions for patients with any opioid-related diagnosis within reporting period.

Create a blueprint to implement the concurrent opioid prescribing nudge intervention in other settings.

Conditions

  • Opioid Use, Unspecified
  • Prescription Drug Abuse (Not Dependent)
  • Prescription Drug Abuse and Dependency
  • Health Behavior
  • Benzodiazepine Abuse
  • Benzodiazepine Dependent

Interventions

OTHER

Automated Reports on prescription patterns for their patients

de-identified aggregate reports

Sponsors & Collaborators

Principal Investigators

  • Charlene Wong, MD · Duke University

  • Charles Scales, MD · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2020-06-15
Completion
2020-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04069403 on ClinicalTrials.gov